Ayca Gucalp

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study”.

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

The Lancet(2023)10.1016/s0140-6736(23)01857-3

N/A

4.7DataRank · unranked

264 citations

Jonathan T. Yang, Juber Patel, Annemarie F. Shepherd, Juliana Eng, Randy Yeh +44 more

Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study

Breast Cancer Research and Treatment(2022)10.1007/s10549-022-06669-2

N/A

0DataRank · unranked

17 citations

Ayca Gucalp, Sujata Patil, Marcia Edelweiss, Dara S. Ross, Pedram Razavi +17 more